Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients
Open accessThe DOI matches its Crossref record; 51 of the 53 references it cites were found in a registry or an index.
Abstract
BACKGROUND: TGF-β has potent profibrotic activity in vitro and has long been implicated in systemic sclerosis (SSc), as expression of TGF-β-regulated genes is increased in the skin and lungs of patients with SSc. Therefore, inhibition of TGF-β may benefit these patients. METHODS: Patients with early, diffuse cutaneous SSc were enrolled in an open-label trial of fresolimumab, a high-affinity neutralizing antibody that targets all 3 TGF-β isoforms. Seven patients received two 1 mg/kg doses of fresolimumab, and eight patients received one 5 mg/kg dose of fresolimumab. Serial mid-forearm skin biopsies, performed before and after treatment, were analyzed for expression of the TGF-β-regulated biomarker genes thrombospondin-1 (THBS1) and cartilage oligomeric protein (COMP) and stained for myofibroblasts. Clinical skin disease was assessed using the modified Rodnan skin score (MRSS). RESULTS: In patient skin, THBS1 expression rapidly declined after fresolimumab treatment in both groups (P = 0.0313 at 7 weeks and P = 0.0156 at 3 weeks), and skin expression of COMP exhibited a strong downward trend in both groups. Clinical skin disease dramatically and rapidly decreased (P < 0.001 at all time points). Expression levels of other TGF-β-regulated genes, including SERPINE1 and CTGF, declined (P = 0.049 and P = 0.012, respectively), and a 2-gene, longitudinal pharmacodynamic biomarker of SSc skin disease decreased after fresolimumab treatment (P = 0.0067). Dermal myofibroblast infiltration also declined in patient skin after fresolimumab (P < 0.05). Baseline levels of THBS1 were predictive of reduced THBS1 expression and improved MRSS after fresolimumab treatment. CONCLUSION: The rapid inhibition of TGF-β-regulated gene expression in response to fresolimumab strongly implicates TGF-β in the pathogenesis of fibrosis in SSc. Parallel improvement in the MRSS indicates that fresolimumab rapidly reverses markers of skin fibrosis. TRIAL REGISTRATION: Clinicaltrials.gov NCT01284322.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a small open label single center study, Fresolimumab (180), a high affinity TGFβ inactivating monoclonal antibody was recently tested in SSc patients, and reduced TGFβ dependent gene expression in skin biopsies and improved modified Rodnan skin score (180).”
From Unraveling SSc Pathophysiology; The Myofibroblast (2018) · cites this paper as [180]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preliminary criteria for the classification of systemic sclerosis (scleroderma)
Masi, A. T., & Subcommittee For Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) · Arthritis & Rheumatism · doi:10.1002/art.1780230510 · Cited by 4,898
Cellular and molecular mechanisms of fibrosis
Wynn, T. (2008) · The Journal of Pathology · doi:10.1002/path.2277 · Cited by 4,495
Scleroderma (systemic sclerosis): classification, subsets and pathogenesis
(2001) · Classic Papers in Rheumatology · doi:10.3109/9780203214237-95 · Cited by 3,950
Open source clustering software
de Hoon, M. J. L., Imoto, S., Nolan, J., & Miyano, S. (2004) · Bioinformatics · doi:10.1093/bioinformatics/bth078 · Cited by 3,043
Roberts, A. B., Sporn, M. B., Assoian, R. K., Smith, J. M., Roche, N. S., Wakefield, L. M., Heine, U. I., Liotta, L. A., Falanga, V, & Kehrl, J. H. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.12.4167 · Cited by 2,866
Desmoulière, A., Geinoz, A., Gabbiani, F., & Gabbiani, G. (1993) · The Journal of cell biology · doi:10.1083/jcb.122.1.103 · Cited by 2,243
Cyclophosphamide versus placebo in scleroderma lung disease
Tashkin, D. P., Elashoff, R., Clements, P. J., Goldin, J., Roth, M. D., Furst, D. E., Arriola, E., Silver, R., Strange, C., Bolster, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055120 · Cited by 1,677
Self-citationTransforming growth factor type beta induces monocyte chemotaxis and growth factor production.
Wahl, S. M., Hunt, D. A., Wakefield, L. M., McCartney-Francis, N., Wahl, L. M., Roberts, A. B., & Sporn, M. B. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.16.5788 · Cited by 1,272
Systemic sclerosis: a prototypic multisystem fibrotic disorder
Varga, J., & Abraham, D. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31139 · Cited by 1,163
Type beta transforming growth factor: a bifunctional regulator of cellular growth.
Roberts, A. B., Anzano, M. A., Wakefield, L. M., Roche, N. S., Stern, D. F., & Sporn, M. B. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.1.119 · Cited by 1,094
Research works printed but not linked: 3
- Derynck R, Miyaono K, eds. The TGF-Beta Family. Cold Spring Harbor Monograph Series 50. Cold Spring Harbor, New York, USA: Cold Spring Harbor Laboratory Press; 2007.
- 10.1002/1529-0131(200011)43:11<2445::AID-ANR11>3.0.CO;2-Q · doi:10.1002/1529-0131(200011)43:11<2445::aid-anr11>3.0.co;2-q
- Rice, Arthritis Rheum.
Cited by
TGF-β: the master regulator of fibrosis
Meng, X.-M., Nikolic-Paterson, D. J., & Lan, H. Y. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.48 · Cited by 3,528
Denton, C. P., & Khanna, D. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30933-9 · Cited by 2,212
Transforming growth factor–β in tissue fibrosis
Frangogiannis, N. G. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20190103 · Cited by 1,278
Liver inflammation and fibrosis
Koyama, Y., & Brenner, D. A. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88881 · Cited by 1,295
TGF-β signaling in health, disease and therapeutics
Deng, Z., Fan, T., Xiao, C., Tian, H., Zheng, Y., Li, C., & He, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01764-w · Cited by 1,168
Khanna, D., Denton, C. P., Jahreis, A., van Laar, J. M., Frech, T. M., Anderson, M. E., Baron, M., Chung, L., Fierlbeck, G., Lakshminarayanan, S., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00232-4 · Cited by 683
Self-citationShared and distinct mechanisms of fibrosis
Distler, J. H. W., Györfi, A.-H., Ramanujam, M., Whitfield, M. L., Königshoff, M., & Lafyatis, R. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0322-7 · Cited by 637
Self-citationTransforming growth factor beta (TGF‐β) isoforms in wound healing and fibrosis
Lichtman, M. K., Otero‐Vinas, M., & Falanga, V. (2016) · Wound Repair and Regeneration · doi:10.1111/wrr.12398 · Cited by 626
Signaling in Fibrosis: TGF-β, WNT, and YAP/TAZ Converge
Piersma, B., Bank, R. A., & Boersema, M. (2015) · Frontiers in Medicine · doi:10.3389/fmed.2015.00059 · Cited by 442
Chen, L., Yang, T., Lu, D.-W., Zhao, H., Feng, Y.-L., Chen, H., Chen, D.-Q., Vaziri, N. D., & Zhao, Y.-Y. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.02.090 · Cited by 359
The Role of Monocytes and Macrophages in Autoimmune Diseases: A Comprehensive Review
Ma, W.-T., Gao, F., Gu, K., & Chen, D.-K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01140 · Cited by 361
Immune dysregulation as a driver of idiopathic pulmonary fibrosis
Shenderov, K., Collins, S. L., Powell, J. D., & Horton, M. R. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143226 · Cited by 295
TGF‐β as a driver of fibrosis: physiological roles and therapeutic opportunities
Budi, E. H., Schaub, J. R., Decaris, M., Turner, S., & Derynck, R. (2021) · The Journal of Pathology · doi:10.1002/path.5680 · Cited by 292
Phage Display Derived Monoclonal Antibodies: From Bench to Bedside
Alfaleh, M. A., Alsaab, H. O., Mahmoud, A. B., Alkayyal, A. A., Jones, M. L., Mahler, S. M., & Hashem, A. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01986 · Cited by 273
Targeting TGF-β signaling for the treatment of fibrosis
Györfi, A. H., Matei, A.-E., & Distler, J. H. W. (2018) · Matrix Biology · doi:10.1016/j.matbio.2017.12.016 · Cited by 274
Myofibroblast transcriptome indicates SFRP2hi fibroblast progenitors in systemic sclerosis skin
Tabib, T., Huang, M., Morse, N., Papazoglou, A., Behera, R., Jia, M., Bulik, M., Monier, D. E., Benos, P. V., Chen, W., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24607-6 · Cited by 267
Self-citationTransforming Growth Factor-β Signaling in Fibrotic Diseases and Cancer-Associated Fibroblasts
Shi, X., Young, C. D., Zhou, H., & Wang, X.-J. (2020) · Biomolecules · doi:10.3390/biom10121666 · Cited by 243
Transforming growth factor–β1 in regulatory T cell biology
Moreau, J. M., Velegraki, M., Bolyard, C., Rosenblum, M. D., & Li, Z. (2022) · Science Immunology · doi:10.1126/sciimmunol.abi4613 · Cited by 243
Targeting TGF-β Signaling for Therapeutic Gain
Akhurst, R. J. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a022301 · Cited by 241
Myofibroblasts: Function, Formation, and Scope of Molecular Therapies for Skin Fibrosis
Tai, Y., Woods, E. L., Dally, J., Kong, D., Steadman, R., Moseley, R., & Midgley, A. C. (2021) · Biomolecules · doi:10.3390/biom11081095 · Cited by 240
In vitro cancer cell–ECM interactions inform in vivo cancer treatment
Holle, A. W., Young, J. L., & Spatz, J. P. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.007 · Cited by 213
TGF-β in fibrosis by acting as a conductor for contractile properties of myofibroblasts
Vallée, A., & Lecarpentier, Y. (2019) · Cell & Bioscience · doi:10.1186/s13578-019-0362-3 · Cited by 194
Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?
Sweeney, M., Corden, B., & Cook, S. A. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201910865 · Cited by 195
Mechanobiology of Tumor Growth
Chaudhuri, P. K., Low, B. C., & Lim, C. T. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00042 · Cited by 192
TGF-β-induced fibrosis: A review on the underlying mechanism and potential therapeutic strategies
Ong, C. H., Tham, C. L., Harith, H. H., Firdaus, N., & Israf, D. A. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174510 · Cited by 183
Immune response patterns in non‐communicable inflammatory skin diseases
Eyerich, K., & Eyerich, S. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14673 · Cited by 179
TGF-beta signal transduction: biology, function and therapy for diseases
Tie, Y., Tang, F., Peng, D., Zhang, Y., & Shi, H. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00109-9 · Cited by 174
Systemic sclerosis: An update in 2016
Desbois, A. C., & Cacoub, P. (2016) · Autoimmunity Reviews · doi:10.1016/j.autrev.2016.01.007 · Cited by 175
TGF-β signaling: critical nexus of fibrogenesis and cancer
Giarratana, A. O., Prendergast, C. M., Salvatore, M. M., & Capaccione, K. M. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05411-4 · Cited by 200
Therapeutic potential of nadph oxidase 1/4 inhibitors
Teixeira, G., Szyndralewiez, C., Molango, S., Carnesecchi, S., Heitz, F., Wiesel, P., & Wood, J. M. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13532 · Cited by 163
Unraveling SSc Pathophysiology; The Myofibroblast
van Caam, A., Vonk, M., van den Hoogen, F., van Lent, P., & van der Kraan, P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02452 · Cited by 153
Wolff, D., Radojčić, V., Lafyatis, R., Çınar, R., Rosenstein, R. K., Cowen, E. W., Cheng, G., Sheshadri, A., Bergeron, A., Williams, K. M., et al. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.06.001 · Cited by 168
Self-citationAutophagy: controlling cell fate in rheumatic diseases
Rockel, J. S., & Kapoor, M. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.92 · Cited by 161
Amini‐Nik, S., Yousuf, Y., & Jeschke, M. G. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.07.017 · Cited by 153
Kumar, R., Mickael, C. S., Kassa, B., Gebreab, L., Robinson, J. C., Koyanagi, D. E., Sanders, L., Barthel, L., Meadows, C. A., Fox, D. L., et al. (2017) · Nature Communications · doi:10.1038/ncomms15494 · Cited by 153
Juhl, P., Bondesen, S., Hawkins, C. L., Karsdal, M. A., Bay‐Jensen, A., Davies, M. J., & Siebuhr, A. S. (2020) · Scientific Reports · doi:10.1038/s41598-020-74179-6 · Cited by 164
TGFβ2 and TGFβ3 isoforms drive fibrotic disease pathogenesis
Sun, T., Huang, Z., Liang, W.-C., Yin, J., Lin, W. Y., Wu, J., Vernes, J.-M., Lutman, J., Caplazi, P., Jeet, S., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0407 · Cited by 134
Emerging targets of disease-modifying therapy for systemic sclerosis
Volkmann, E. R., & Varga, J. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0184-z · Cited by 145
Asano, Y. (2017) · The Journal of Dermatology · doi:10.1111/1346-8138.14153 · Cited by 146
Yun, S., Kim, S., & Kim, E. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00162 · Cited by 130
The Extracellular Matrix: An Accomplice in Gastric Cancer Development and Progression
Moreira, A. M., Pereira, J., Melo, S., Fernandes, M. S., Carneiro, P., Seruca, R., & Figueiredo, J. (2020) · Cells · doi:10.3390/cells9020394 · Cited by 118
Allanore, Y., Distler, O., Jagerschmidt, A., Illiano, S., Ledein, L., Boitier, E., Agueusop, I., Denton, C. P., & Khanna, D. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40547 · Cited by 113
Rice, L. M., Ziemek, J., Stratton, E. A., McLaughlin, S. R., Padilla, C. M., Mathes, A. L., Christmann, R. B., Stifano, G., Browning, J. L., Whitfield, M. L., et al. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39287 · Cited by 106
Self-citationOsteogenesis Imperfecta: Current and Prospective Therapies
Botor, M., Fus-Kujawa, A., Uroczynska, M., Stępień, K., Galicka, A., Gawron, K., & Sieroń, A. L. (2021) · Biomolecules · doi:10.3390/biom11101493 · Cited by 144
Zhang, J., Hu, Z., Horta, C. A., & Yang, J. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.12.002 · Cited by 113
Targeting TGF-β for treatment of osteogenesis imperfecta
Song, I.-W., Nagamani, S. C. S., Nguyen, D., Grafe, I., Sutton, V. R., Gannon, F. H., Munivez, E., Jiang, M., Tran, A., Wallace, M. J., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci152571 · Cited by 107
Comprehensive Insights into Keloid Pathogenesis and Advanced Therapeutic Strategies
Kim, H. J., & Kim, Y. H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168776 · Cited by 116
Current perspectives on the immunopathogenesis of systemic sclerosis
Fuschiotti, P. (2016) · ImmunoTargets and Therapy · doi:10.2147/itt.s82037 · Cited by 109
Interstitial lung disease in systemic sclerosis: current and future treatment
Giacomelli, R., Liakouli, V., Berardicurti, O., Ruscitti, P., Benedetto, P. D., Carubbi, F., Guggino, G., Bartolomeo, S. D., Ciccia, F., Triolo, G., et al. (2017) · Rheumatology International · doi:10.1007/s00296-016-3636-7 · Cited by 103
Pathogenesis of systemic sclerosis—current concept and emerging treatments
Furue, M., Mitoma, C., Mitoma, H., Tsuji, G., Chiba, T., Nakahara, T., Uchi, H., & Kadono, T. (2017) · Immunologic Research · doi:10.1007/s12026-017-8926-y · Cited by 101
The clinical manifestations and molecular pathogenesis of radiation fibrosis
Fijardo, M., Kwan, J. Y. Y., Bissey, P.-A., Citrin, D. E., Yip, K. W., & Liu, F. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105089 · Cited by 104
Evolving insights into the cellular and molecular pathogenesis of fibrosis in systemic sclerosis
Korman, B. D. (2019) · Translational research · doi:10.1016/j.trsl.2019.02.010 · Cited by 93
Characterizing the “POAGome”: A bioinformatics-driven approach to primary open-angle glaucoma
Danford, I. D., Verkuil, L. D., Choi, D. J., Collins, D. W., Gudiseva, H. V., Uyhazi, K. E., Lau, M. K., Kanu, L. N., Grant, G. R., Chavali, V. R. M., et al. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.02.001 · Cited by 90
Clinical Treatment Options in Scleroderma: Recommendations and Comprehensive Review
Zhao, M. F., Wu, J., Wu, H., Sawalha, A. H., & Lu, Q. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-020-08831-4 · Cited by 97
Li, Y., Fan, W., Link, F., Wang, S., & Dooley, S. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2021.100397 · Cited by 79
Schulz, J.-N., Plomann, M., Sengle, G., Gullberg, D., Krieg, T., & Eckes, B. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.01.025 · Cited by 86
Systemic Sclerosis Pathogenesis and Emerging Therapies, beyond the Fibroblast
Sierra-Sepúlveda, A., Esquinca-González, A., Benavides-Suárez, S. A., Sordo-Lima, D. E., Caballero-Islas, A. E., Cabral-Castañeda, A. R., & Rodríguez-Reyna, T. S. (2019) · BioMed Research International · doi:10.1155/2019/4569826 · Cited by 103
CXCL4 drives fibrosis by promoting several key cellular and molecular processes
Affandi, A. J., Carvalheiro, T., Ottria, A., de Haan, J. J., Brans, M. A. D., Brandt, M. M., Tieland, R. G., Lopes, A. P., Malvar‐Fernández, B., Bekker, C. P. J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2021.110189 · Cited by 93
Major lung complications of systemic sclerosis
Denton, C. P., Wells, A. U., & Coghlan, G. (2018) · Nature Reviews Rheumatology · doi:10.1038/s41584-018-0062-0 · Cited by 91
Immune cell dysregulation as a mediator of fibrosis in systemic sclerosis
Fang, D., Chen, B., Lescoat, A., Khanna, D., & Mu, R. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-022-00864-7 · Cited by 84
Review: Frontiers of Antifibrotic Therapy in Systemic Sclerosis
Distler, J. H. W., Feghali‐Bostwick, C., Soare, A., Asano, Y., Distler, O., & Abraham, D. J. (2017) · Arthritis & Rheumatology · doi:10.1002/art.39865 · Cited by 82
Apostolidis, S. A., Stifano, G., Tabib, T., Rice, L. M., Morse, C., Kahaleh, B., & Lafyatis, R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02191 · Cited by 84
Self-citationXiong, J., Xiao, R., Zhao, J., Zhao, Q., Luo, M., Li, F., Zhang, W., & Wu, M. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-023-04810-3 · Cited by 79
“In addition, fresolimumab treat-ment decreases biomarkers of thrombospondin-1 and cartilage oligomeric protein and improves clinical symptoms in systemic sclerosis patients [130].”
BackgroundType 2 Inflammation in Eosinophilic Esophagitis: From Pathophysiology to Therapeutic Targets
Racca, F., Pellegatta, G., Cataldo, G., Vespa, E., Carlani, E., Pelaia, C., Paoletti, G., Messina, M., Nappi, E., Canonica, G. W., et al. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2021.815842 · Cited by 91
Cartilage Oligomeric Matrix Protein, Diseases, and Therapeutic Opportunities
Cui, J., & Zhang, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169253 · Cited by 77
“TGF-β signaling is critical for skin fibrosis [28,127].”
BackgroundDufour, A. M., Alvarez, M., Russo, B., & Chizzolini, C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01865 · Cited by 73
Emerging therapeutic targets for the treatment of hepatic fibrosis
Fagone, P., Mangano, K., Pesce, A., Portale, T. R., Puleo, S., & Nicoletti, F. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.10.015 · Cited by 77
Hanada, T., Tsuji, S., Nakayama, M., Wakinoue, S., Kasahara, K., Kimura, F., Mori, T., Ogasawara, K., & Murakami, T. (2018) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-018-0325-2 · Cited by 81
Meng, S., Wei, Q., Chen, S., Liu, X., Cui, S., Huang, Q., Chu, Z., Ma, K., Zhang, W., Hu, W., et al. (2023) · Small · doi:10.1002/smll.202305374 · Cited by 90
Autoimmunity as the comet tail of COVID-19 pandemic
Talotta, R., & Robertson, E. S. (2020) · World Journal of Clinical Cases · doi:10.12998/wjcc.v8.i17.3621 · Cited by 76
Role of B-Cell in the Pathogenesis of Systemic Sclerosis
Thoreau, B., Chaigne, B., & Mouthon, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.933468 · Cited by 78
Fang, F., Marangoni, R. G., Zhou, X., Yang, Y., Ye, B., Shangguang, A., Qin, W., Wang, W., Bhattacharyya, S., Wei, J., et al. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39655 · Cited by 71
Transforming growth factor-β signaling in systemic sclerosis
Nolan, B., Chenming, S., & Chen, S. (2018) · Journal of Biomedical Research · doi:10.7555/jbr.31.20170034 · Cited by 71
Cherry, C., Andorko, J. I., Krishnan, K., Mejías, J. C., Nguyen, H. H., Stivers, K. B., Gray-Gaillard, E. F., Ruta, A., Han, J., Hamada, N., et al. (2023) · GeroScience · doi:10.1007/s11357-023-00785-7 · Cited by 66
McCoy, S. S., Reed, T. J., Berthier, C. C., Tsou, P., Liu, J. J., Gudjonsson, J. E., Khanna, D., & Kahlenberg, J. M. (2017) · Rheumatology · doi:10.1093/rheumatology/kex280 · Cited by 75
Involvement of the myeloid cell compartment in fibrogenesis and systemic sclerosis
Kania, G., Rudnik, M., & Distler, O. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0212-z · Cited by 71
Macrophages in Systemic Sclerosis: Novel Insights and Therapeutic Implications
Toledo, D. M., & Pioli, P. A. (2019) · Current Rheumatology Reports · doi:10.1007/s11926-019-0831-z · Cited by 64
TGF-β Pathway in Salivary Gland Fibrosis
Zhang, X., Yun, J. S., Han, D., Yook, J. I., Kim, H. S., & Cho, E. S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239138 · Cited by 70
Biomarkers in systemic sclerosis: Their potential to predict clinical courses
Hasegawa, M. (2016) · The Journal of Dermatology · doi:10.1111/1346-8138.13156 · Cited by 66
Yamakawa, T., Ohigashi, H., Hashimoto, D., Hayase, E., Takahashi, S., Miyazaki, M., Minomi, K., Onozawa, M., Niitsu, Y., & Teshima, T. (2018) · Blood · doi:10.1182/blood-2017-04-779934 · Cited by 64
Stifano, G., Sornasse, T., Rice, L. M., Na, L., Chen‐Harris, H., Khanna, D., Jahreis, A., Zhang, Y., Siegel, J., & Lafyatis, R. (2018) · Arthritis & Rheumatology · doi:10.1002/art.40455 · Cited by 62
Self-citationTumor in the Crossfire: Inhibiting TGF-β to Enhance Cancer Immunotherapy
Tschernia, N. P., & Gulley, J. L. (2022) · BioDrugs · doi:10.1007/s40259-022-00521-1 · Cited by 64
Oparaugo, N. C., Ouyang, K., Nguyen, N. P. N., Nelson, A. M., & Agak, G. W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021527 · Cited by 66
Zhu, H., Luo, H., Skaug, B. A., Tabib, T., Li, Y., Tao, Y., Matei, A., Lyons, M. A., Schett, G. A., Lafyatis, R., et al. (2023) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2023.09.288 · Cited by 72
Self-citationTherapeutic pro-fibrogenic signaling pathways in fibroblasts
Cannito, S., Novo, E., & Parola, M. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.017 · Cited by 62
Altered Dermal Fibroblasts in Systemic Sclerosis Display Podoplanin and CD90
Nazari, B., Rice, L. M., Stifano, G., Barron, A., Wang, Y. M., Korndorf, T., Lee, J. E., Bhawan, J., Lafyatis, R., & Browning, J. L. (2016) · American Journal Of Pathology · doi:10.1016/j.ajpath.2016.06.020 · Cited by 66
Self-citationPTP4A1 promotes TGFβ signaling and fibrosis in systemic sclerosis
Sacchetti, C., Bai, Y., Stanford, S. M., Benedetto, P. D., Cipriani, P., Santelli, E., Piera-Velázquez, S., Chernitskiy, V., Kiosses, W. B., Ceponis, A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01168-1 · Cited by 62
Idiopathic pulmonary fibrosis and lung cancer: future directions and challenges
Qubo, A. A., Numan, J., Snijder, J., Padilla, M. L., Austin, J. H. M., Capaccione, K. M., Pernia, M., Bustamante, J., O'Connor, T., & Salvatore, M. M. (2022) · Breathe · doi:10.1183/20734735.0147-2022 · Cited by 65
Existing and novel biomarkers for precision medicine in systemic sclerosis
Wermuth, P. J., Piera-Velázquez, S., Rosenbloom, J., & Jiménez, S. A. (2018) · Nature Reviews Rheumatology · doi:10.1038/s41584-018-0021-9 · Cited by 59
Actin Cytoskeleton and Regulation of TGFβ Signaling: Exploring Their Links
Melchionna, R., Trono, P., Tocci, A., & Nisticò, P. (2021) · Biomolecules · doi:10.3390/biom11020336 · Cited by 63
Lafyatis, R., Mantero, J. C., Gordon, J., Kishore, N., Carns, M., Dittrich, H., Spiera, R., Simms, R. W., & Varga, J. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.06.032 · Cited by 59
Self-citationMolecular Profiling Reveals a Common Metabolic Signature of Tissue Fibrosis
Zhang, J., Muise, E. S., Han, S., Kutchukian, P. S., Costet, P., Zhu, Y., Kan, Y., Zhou, H., Shah, V., Huang, Y., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100056 · Cited by 59
Lescoat, A., Varga, J., Matucci‐Cerinic, M., & Khanna, D. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1923693 · Cited by 57
The current landscape of antifibrotic therapy across different organs: A systematic approach
Fuster‐Martínez, I., & Calatayud, S. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107245 · Cited by 64
Cytokine and anti-cytokine therapies in prevention or treatment of fibrosis in IBD
Jacob, N., Targan, S. R., & Shih, D. Q. (2016) · United European Gastroenterology Journal · doi:10.1177/2050640616649356 · Cited by 53
Signaling Pathways and Potential Therapeutic Strategies in Cardiac Fibrosis
Foucault‐Bertaud, A., Joshkon, A., Heim, X., Bachelier, R., Bardin, N., Leroyer, A. S., & Blot‐Chabaud, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021756 · Cited by 56
Cipriani, P., Di Benedetto, P., Ruscitti, P., Liakouli, V., Berardicurti, O., Carubbi, F., Ciccia, F., Guggino, G., Zazzeroni, F., Alesse, E., et al. (2016) · The Journal of Rheumatology · doi:10.3899/jrheum.150996 · Cited by 51
Dendritic cells maintain dermal adipose–derived stromal cells in skin fibrosis
Chia, J. J., Zhu, T., Chyou, S., Dasoveanu, D. C., Carballo, C., Tian, S., Magro, C. M., Rodeo, S., Spiera, R. F., Ruddle, N. H., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85740 · Cited by 50
Self-citationPark, J.-S., Oh, Y., Park, Y. J., Park, O., Yang, H. S., Slania, S., Hummers, L. K., Shah, A. A., An, H.-T., Jang, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09101-4 · Cited by 52
Engineered antigen-specific regulatory T cells for autoimmune skin conditions
Mukhatayev, Z., Ostapchuk, Y. O., Fang, D., & Poole, I. C. L. (2021) · Autoimmunity Reviews · doi:10.1016/j.autrev.2021.102761 · Cited by 56
Metadata
- Authors
- Rice, L. M., Padilla, C. M., McLaughlin, S. R., Mathes, A., Ziemek, J., Goummih, S., Nakerakanti, S., York, M., Farina, G., Whitfield, M. L., Spiera, R. F., Christmann, R. B., Gordon, J. K., Weinberg, J., Simms, R. W., & Lafyatis, R.
- Affiliations
- Boston University (US)
- Hospital for Special Surgery (US)
- Dartmouth College (US)
- Corresponding author
- Lafyatis, Robert
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2015-06-22
- Volume
- 125
- Issue
- 7
- Pages
- 2795-2807
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC4563675
- OpenAlex
- W2155049325
- Cited by
- 351
- References
- 53
- Citations by year
- 2026: 19 · 2025: 26 · 2024: 30 · 2023: 27 · 2022: 37 · 2021: 30 · 2020: 28 · 2019: 24 · 2018: 42 · 2017: 41 · 2016: 34 · 2015: 13
- FWCI
- 34.42
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Scleroderma Research Foundation
- Bristol-Myers Squibb
- GlaxoSmithKline
- Gilead Sciences
- Alexion Pharmaceuticals
- Celgene
- United Therapeutics Corporation
- Dr. Ralph and Marian Falk Medical Research Trust
- Hospital for Special Surgery
- Cytori Therapeutics
- National Institutes of Health
- Genentech
- Clinical and Translational Science Institute, Boston University
- National Cancer Institute (P30CA023108)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR051089, R03AR062721, P30AR061271, P50AR060780)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Connective tissue disorders research
- Health Sciences › Medicine › Rheumatology › Dupuytren's Contracture and Treatments
- Keywords
- systemic sclerosis, diffuse cutaneous systemic sclerosis, TGF-beta inhibition, skin fibrosis, thrombospondin-1, cartilage oligomeric matrix protein, myofibroblasts, connective tissue growth factor, SERPINE1, modified Rodnan skin score, pharmacodynamic biomarkers, neutralizing antibodies
- MeSH terms
- Adult, Antibodies, Monoclonal, Female, Genetic Markers, Humans, Male, Middle Aged, Scleroderma, Systemic, Gene Expression, Transforming Growth Factor beta, Treatment Outcome, Thrombospondin 1, Myofibroblasts, Antibodies, Monoclonal, Humanized, Cartilage Oligomeric Matrix Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.